ERBB2 and breast cancer: Novel biomarkers, such as Oncotype DX and MammaPrint, are complementing traditional ones—estrogen and progesterone receptors, and human epidermal growth factor receptor 2 (HER2)—as efficient prevention and prognostic tools for breast cancer [171].